Capricorn Fund Managers Ltd Buys 247,000 Shares of Roivant Sciences Ltd. $ROIV

Capricorn Fund Managers Ltd raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 124.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 445,500 shares of the company’s stock after buying an additional 247,000 shares during the quarter. Roivant Sciences accounts for about 2.3% of Capricorn Fund Managers Ltd’s portfolio, making the stock its 11th largest position. Capricorn Fund Managers Ltd owned approximately 0.06% of Roivant Sciences worth $9,667,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Jones Financial Companies Lllp raised its position in shares of Roivant Sciences by 226.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after acquiring an additional 1,148 shares during the period. Allworth Financial LP grew its holdings in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares during the period. Bessemer Group Inc. grew its holdings in Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the period. Osaic Holdings Inc. increased its stake in Roivant Sciences by 204.2% in the second quarter. Osaic Holdings Inc. now owns 5,783 shares of the company’s stock valued at $65,000 after purchasing an additional 3,882 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd increased its stake in Roivant Sciences by 75.8% in the third quarter. Aster Capital Management DIFC Ltd now owns 4,405 shares of the company’s stock valued at $67,000 after purchasing an additional 1,900 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Citigroup lifted their price target on shares of Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. Sanford C. Bernstein assumed coverage on Roivant Sciences in a research note on Friday, March 20th. They set an “outperform” rating and a $35.00 price objective on the stock. Guggenheim lifted their target price on Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Jefferies Financial Group reissued a “buy” rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Finally, The Goldman Sachs Group increased their price target on Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $29.50.

Roivant Sciences Price Performance

Roivant Sciences stock opened at $28.33 on Monday. The company has a 50 day moving average of $26.80 and a 200-day moving average of $22.28. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $30.33. The stock has a market capitalization of $20.28 billion, a PE ratio of -24.21 and a beta of 1.20.

Insider Transactions at Roivant Sciences

In other news, Director Daniel Allen Gold sold 425,000 shares of the business’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $26.67, for a total value of $11,334,750.00. Following the sale, the director directly owned 15,928,113 shares in the company, valued at $424,802,773.71. The trade was a 2.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Melissa B. Epperly sold 41,861 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $28.68, for a total value of $1,200,573.48. Following the transaction, the director directly owned 15,804 shares of the company’s stock, valued at $453,258.72. This represents a 72.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 4,782,086 shares of company stock worth $128,848,063. Company insiders own 10.80% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.